查看購物車
  • English
  • Japanese
全球多重檢測市場：依產品/服務、類型、技術、應用、最終用戶和地區分類－預測至2031年
市場調查報告書
商品編碼
2043692

全球多重檢測市場：依產品/服務、類型、技術、應用、最終用戶和地區分類－預測至2031年

Multiplex Assays Market by Product & Service (Consumable, Instrument), Type (Protein, Nucleic Acid), Technology (Flow Cytometry), Application, End User (Hospital, Research Institute)-Global Forecast to 2031
出版日期: | 出版商: MarketsandMarkets | 英文 410 Pages | 訂單完成後即時交付

價格

預計到 2026 年，多重檢測市場規模將達到約 71.5 億美元，到 2031 年將達到 106.5 億美元，複合年成長率為 8.3%。

這一穩定成長歸功於醫療機構越來越重視早期診斷、準確的生物標記和改善患者預後。

調查範圍
調查期 2026-2031
基準年 2025
預測期 2026-2031
目標單元 金額（10億美元）
部分 按產品/服務、類型、技術、應用程式、最終用戶和地區分類。
目標區域 北美洲、歐洲、亞太地區、中東和非洲、拉丁美洲

疾病日益複雜化、個人化醫療的興起以及對高效、高通量檢測方法的需求等因素，正在推動全球對多重檢測的需求不斷成長。

多重檢測市場-IMG1

“按產品和服務細分市場來看，預計在預測期內，耗材細分市場的複合年成長率將最高。”

此領域的成長主要受多重檢測試劑盒、試劑、磁珠、引子、探針和對照品等分析必需品的持續需求所驅動。感染疾病、癌症和自體免疫疾病的日益流行預計將增加各醫療機構的檢測需求。這將擴大醫院、診斷檢查室和研究機構對該領域的需求。此外，多重檢測方案的廣泛應用和新型檢測方法的開發預計也將進一步促進這一成長。

“按技術分類，預計到 2026 年，流式細胞技術將在多重檢測市場中佔據最大佔有率。”

由於該技術在醫院和實驗室的廣泛應用，使得生物標記和細胞分析能夠進行高通量、多參數檢測，並顯著提高靈敏度、準確性和可重複性，因此該細分市場佔據主導地位。流式細胞技術因其能夠在一次檢測中快速分析多種標記物，已成為免疫學、腫瘤學和轉化研究領域應用最廣泛的儀器之一。對流式細胞儀的需求主要源自於診斷檢測和科學研究的成長，以及疾病譜分析和治療監測的需求。

“預計亞太地區將在多重檢測市場中錄得最高的成長率。”

亞太地區正經歷快速成長，這主要得益於多種因素，包括醫療設施的擴張和醫療支出的成長。醫院、檢查室和診斷中心的現代化也促進了這一成長。此外，感染疾病、癌症和慢性病發病率的上升也推動了對先進診斷檢測的需求。同時，生物技術研究投入的增加、製藥生產設施的擴張以及診斷中心的增多，也促進了亞太地區多重檢測技術的發展。推動這一市場成長的主要國家包括中國、印度、日本和韓國。

多重檢測市場的主要參與者包括 Thermo Fisher Scientific, Inc.（美國）、Illumina, Inc.（美國）、Bio-Rad Laboratories, Inc.（美國）、QIAGEN NV（荷蘭）、Danaher Corporation（美國）、Becton, Dickinson and Company（美國）、Merck KGaA（德國）、DiaSod, H.A. Ltd.（瑞士）、Agilent Technologies（美國）、Quanterix Corporation（美國）和 bioMerieux（法國）。

調查範圍：

本研究報告按產品和服務（耗材、設備、軟體和服務）、類型（蛋白質多重檢測、核酸多重檢測、基於細胞的多重檢測）、技術（流式細胞技術、螢光檢測、多重即時PCR、分子冷光、次世代定序（NGS）和其他技術）、應用（研發、臨床診斷）、最終用戶（製藥和生物技術公司、醫院和診斷實驗室、學術和研究機構、受託研究機構和其他最終用戶）以及地區（北美、歐洲、亞太地區、拉丁美洲以及中東和非洲）對多重檢測市場進行細分。

本報告深入分析了影響多重檢測市場成長的關鍵因素，包括促進因素、限制因素、機會和挑戰。報告詳細分析了主要行業參與者，深入剖析了他們的業務概況、解決方案、夥伴關係、聯盟、擴張計劃、協議、新產品發布以及在多重檢測市場中的關鍵戰略。此外，報告還對多重檢測市場生態系統中新興的新創公司進行了競爭分析。

購買本報告的理由：

本報告透過提供多重檢測市場及其細分市場最準確的收入估算，幫助市場領導和新參與企業更了解市場。它幫助相關人員了解競爭格局，獲得更深入的洞察，合理定位業務，並制定有效的打入市場策略。此外，本報告還幫助相關人員了解市場趨勢，並提供有關關鍵促進因素、限制因素、機會和挑戰的資訊。

本報告深入分析了以下幾點：

  • 本報告分析了關鍵促進因素（慢性疾病和感染疾病的發病率上升、優於單重和傳統檢測、伴隨診斷中多重檢測的日益普及、對早期疾病檢測的日益重視）、阻礙因素（成本限制、監管挑戰以及與多重檢測設備相關的嚴格質量標準）、機遇（分子和感染疾病診斷中生物標記檢驗的擴展、分子和蛋白質診斷中生物標記的解釋以及新興市場中生物標記的解釋以及新興市場中生物標記的進展）以及新興市場中生物標記的解釋以及新興市場的進步和研究領域的研究因素以及新興市場的進步。
  • 產品開發/創新：深入了解多重檢測市場的未來技術、研發活動和新產品發布。
  • 市場發展：提供盈利市場的全面資訊。本報告分析了各地區的多重檢測市場。
  • 市場多元化：提供有關多重檢測市場的新產品、未開發市場、最新趨勢和投資的全面資訊。

競爭分析：對 Thermo Fisher Scientific, Inc.（美國）、Illumina, Inc.（美國）、Bio-Rad Laboratories, Inc.（美國）、DiaSorin SpA（義大利）和 bioMerieux（法國）等主要公司的市場佔有率、成長策略和產品陣容進行詳細評估。

目錄

第1章：引言

第2章執行摘要

第3章重要考察

第4章 市場概覽

  • 市場動態
    • 促進因素
    • 抑制因子
    • 機會
    • 任務
  • 未滿足的需求和未開發的領域
  • 相互關聯的市場與跨產業機遇
  • 一級/二級/三級公司的策略性舉措

第5章 產業趨勢

  • 波特五力分析
  • 總體經濟指標
  • 供應鏈分析
  • 價值鏈分析
  • 生態系分析
  • 價格分析
  • 貿易分析
  • 2026-2027 年主要會議和活動
  • 影響客戶業務的趨勢/顛覆性因素
  • 投資和資金籌措場景
  • 2025年美國關稅對多重檢測市場的影響

第6章：技術進步、人工智慧的影響、專利、創新與未來應用

  • 關鍵新興技術
  • 互補技術
  • 鄰近技術
  • 技術/產品藍圖
  • 專利分析
  • 未來應用
  • 人工智慧/生成式人工智慧對多重偵測市場的影響

第7章：監理情勢與永續性舉措

  • 當地法規和合規性
  • 對永續性的承諾
  • 監理政策對永續性舉措的影響

第8章：顧客趨勢與購買行為

  • 決策流程
  • 採購過程中的關鍵相關人員及其評估標準
  • 實施障礙和內部挑戰
  • 各個終端用戶產業尚未滿足的需求
  • 市場盈利

第9章：多重檢測市場（依產品/服務分類）

  • 消耗品
  • 裝置
  • 軟體與服務

第10章：多重檢測市場（按類型分類）

  • 蛋白質多重檢測
  • 核酸多重檢測
  • 基於細胞的多重檢測

第11章：多重檢測市場（依技術分類）

  • 流式細胞技術
  • 螢光偵測
  • 多重即時PCR
  • 發光的
  • 次世代定序（NGS）
  • 其他

第12章：多重檢測市場（依應用領域分類）

  • 研究與開發
  • 臨床診斷

第13章：多重偵測市場（依最終用戶分類）

  • 製藥和生物技術公司
  • 醫院和診斷檢測實驗室
  • 學術和研究機構
  • 合約研究機構
  • 其他

第14章：多重檢測市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第15章 競爭格局

  • 2023-2026年主要參與企業的競爭策略/優勢
  • 2023-2025年收入分析
  • 2025年市佔率分析
  • 企業估值矩陣：主要公司，2025 年
  • 公司估值矩陣：新創企業/中小企業，2025 年
  • 企業估值和財務指標
  • 品牌/產品對比
  • 競爭格局

第16章：公司簡介

  • 主要參與企業
    • ILLUMINA, INC.
    • BIO-RAD LABORATORIES, INC.
    • THERMO FISHER SCIENTIFIC INC.
    • DIASORIN SPA
    • BIOMERIEUX
    • BECTON, DICKINSON AND COMPANY
    • QIAGEN NV
    • MERCK KGAA
    • AGILENT TECHNOLOGIES, INC.
    • DANAHER CORPORATION
    • REVVITY, INC.
    • F. HOFFMANN-LA ROCHE LTD
    • QUANTERIX CORPORATION
  • 其他公司
    • BIO-TECHNE CORPORATION
    • SEEGENE INC.
    • MESO SCALE DIAGNOSTICS LLC
    • RANDOX LABORATORIES LTD.
    • STANDARD BIOTOOLS INC.
    • HOLOGIC, INC.
    • ABBOTT LABORATORIES
    • SIEMENS HEALTHINEERS AG
    • ENZO BIOCHEM INC.
    • SHIMADZU CORPORATION
    • PROMEGA CORPORATION
    • BOSTER BIOLOGICAL TECHNOLOGY

第17章調查方法

第18章附錄

Product Code: MD 4473

The market for multiplex assays is projected to be valued at approximately USD 7.15 billion in 2026 and is expected to reach USD 10.65 billion by 2031, reflecting a 8.3% growth rate. This steady growth is driven by medical institutions' growing focus on early diagnosis, accurate biomarkers, and improved patient outcomes.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsProduct & Service, Type, Technology, Application, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Middle East & Africa, Latin America

Factors such as the increasing complexity of diseases, the rise of personalized medicine, and the need for efficient, high-throughput testing methods are driving the growing global demand for multiplex assays.

Multiplex Assays Market - IMG1

"By product & service, the consumables segment is predicted to showcase the highest CAGR during the forecast period."

The growth in this segment is primarily driven by the consistent need for multiplex assay kits, reagents, beads, primers, probes, and controls, all of which are essential for conducting analyses. The rising incidence of infectious diseases, cancers, and autoimmune conditions is expected to increase testing demand across various healthcare settings. This will boost demand for the segment in hospitals, diagnostic labs, and research facilities. Additionally, the expanding use of multiplex testing protocols and the development of new assays will further contribute to this growth.

"By technology, the Flow cytometry segment is projected to hold the largest share of the multiplex assay market in 2026."

This market segment is dominant due to the widespread adoption of technology in hospitals and reference laboratories, enabling high-throughput and multiparametric testing with improved sensitivity, accuracy, and reproducibility in biomarker and cell analysis. Flow cytometry is among the most widely used instruments in immunology, oncology, and translational research, owing to its ability to rapidly analyze multiple markers in a single test. The demand for flow cytometers is primarily driven by the increasing number of diagnostic tests, scientific studies, and the need for disease profiling and therapy monitoring.

"The Asia Pacific is expected to register the fastest growth rate in the multiplex assay market."

This region is experiencing rapid growth due to several factors, including the expansion of healthcare facilities and increased healthcare spending. The modernization of hospitals, laboratories, and diagnostic centers is also contributing to this growth. Additionally, the rising incidence of infectious diseases, cancer, and chronic conditions is driving the demand for advanced diagnostic tests. Furthermore, increased investments in biotechnology research, the expansion of pharmaceutical production facilities, and a growing number of diagnostic centers are fueling the growth of multiplex assays in the Asia Pacific region. Key countries contributing to this market growth include China, India, Japan, and South Korea, among others.

The break-up of the profile of primary participants in the multiplex assay market:

  • By Company Type: Tier 1 (35%), Tier 2 (40%), and Tier 3 (15%)
  • By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%)
  • By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)

The key players in the multiplex assay market are Thermo Fisher Scientific, Inc. (US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Danaher Corporation (US), Becton, Dickinson and Company (US), Merck KGaA (Germany), DiaSorin S.p.A. (Italy), Revvity, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies (US), Quanterix Corporation (US), and bioMerieux (France).

Research Coverage:

This research report categorizes the multiplex assay market by product & service (consumables, instruments, software & services), type (protein multiplex assays, nucleic acid multiplex assays, cell-based multiplex assays), technology (flow cytometry, fluorescence detection, multiplex real-time PCR, luminescence, next-generation sequencing (NGS), other technologies), application (research & development, clinical diagnostics), end user (pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, contract research organizations, other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the multiplex assay market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, key strategies, such as partnerships, collaborations, expansions, agreements, new product launches, and recent developments in the multiplex assay market. This report covers the competitive analysis of upcoming startups in the multiplex assay market ecosystem.

Reasons to buy this report:

The report will help market leaders/new entrants in this market by providing information on the closest approximations of revenue for the overall multiplex assay market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

  • Analysis of key drivers (rising incidence of chronic and infectious diseases, advantages over singleplex and traditional assays, increasing use of multiplex assays in companion diagnostics, growing focus on early disease detection, rising incidence of chronic and infectious diseases), restraints (cost constraints associated with multiplex assay instrumentation, regulatory challenges and stringent quality standards), opportunities (growing validation of biomarkers in molecular and protein-based diagnostics, advancements in biomarker validation in molecular and protein diagnostics, expansion in emerging markets), and challenges (shortage of skilled professionals, complex data analysis and interpretation).
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the multiplex assay market.
  • Market Development: Comprehensive information about lucrative markets; the report analyses the multiplex assay market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the multiplex assay market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Thermo Fisher Scientific, Inc. (US), Illumina, Inc (US), Bio-Rad Laboratories, Inc. (US), DiaSorin S.p.A. (Italy), and bioMerieux (France).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS IN MULTIPLEX ASSAY MARKET
  • 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
  • 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN MULTIPLEX ASSAY MARKET
  • 3.2 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031
  • 3.3 MULTIPLEX ASSAY MARKET, BY TYPE, 2026 VS. 2031
  • 3.4 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2026 VS. 2031
  • 3.5 MULTIPLEX ASSAY MARKET, BY APPLICATION, 2026 VS. 2031
  • 3.6 MULTIPLEX ASSAY MARKET, BY END USER, 2026 VS. 2031
  • 3.7 MULTIPLEX ASSAY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Rising incidence of chronic and infectious diseases
      • 4.2.1.2 Advantages over singleplex and traditional assays
      • 4.2.1.3 Increasing use of multiplex assays in companion diagnostics
      • 4.2.1.4 Growing focus on early disease detection
      • 4.2.1.5 Expansion of biomarker-driven research
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Cost constraints associated with multiplex assay instrumentation
      • 4.2.2.2 Regulatory challenges and stringent quality standards
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Growing validation of biomarkers in molecular and protein-based diagnostics
      • 4.2.3.2 Expansion in emerging markets
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Shortage of skilled professionals
      • 4.2.4.2 Complex data analysis and interpretation
  • 4.3 UNMET NEEDS AND WHITE SPACES
    • 4.3.1 UNMET NEEDS IN MULTIPLEX ASSAY MARKET
    • 4.3.2 WHITE SPACE OPPORTUNITIES
  • 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
    • 4.4.1 INTERCONNECTED MARKETS
    • 4.4.2 CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
    • 4.5.1 KEY MOVES AND STRATEGIC FOCUS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF NEW ENTRANTS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC INDICATORS
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS AND FORECAST
  • 5.3 SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
    • 5.5.1 MULTIPLEX ASSAY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • 5.6 PRICING ANALYSIS
    • 5.6.1 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY KEY PLAYER, 2024-2026
    • 5.6.2 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY REGION, 2024-2026
  • 5.7 TRADE ANALYSIS
    • 5.7.1 IMPORT SCENARIO (HS CODE 3822)
    • 5.7.2 EXPORT SCENARIO (HS CODE 3822)
  • 5.8 KEY CONFERENCES AND EVENTS, 2026-2027
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.10 INVESTMENT AND FUNDING SCENARIO
  • 5.11 IMPACT OF 2025 US TARIFF ON MULTIPLEX ASSAY MARKET
    • 5.11.1 INTRODUCTION
    • 5.11.2 KEY TARIFF RATES
    • 5.11.3 PRICE IMPACT ANALYSIS
    • 5.11.4 IMPACT ON REGION
      • 5.11.4.1 North America
      • 5.11.4.2 Europe
      • 5.11.4.3 Asia Pacific
    • 5.11.5 IMPACT ON END-USE INDUSTRIES

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 MULTIPLEX REAL-TIME PCR
    • 6.1.2 FLOW CYTOMETRY
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 BIOINFORMATICS
    • 6.2.2 MICROFLUIDICS
  • 6.3 ADJACENT TECHNOLOGIES
    • 6.3.1 NEXT-GENERATION SEQUENCING
    • 6.3.2 DIGITAL PCR
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PATENT ANALYSIS
    • 6.5.1 LIST OF KEY PATENTS
  • 6.6 FUTURE APPLICATIONS
  • 6.7 IMPACT OF AI/GENERATIVE AI ON MULTIPLEX ASSAY MARKET
    • 6.7.1 INTRODUCTION
    • 6.7.2 TOP USE CASES AND MARKET POTENTIAL
    • 6.7.3 KEY COMPANIES IMPLEMENTING AI
    • 6.7.4 FUTURE OF AI

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.2 SUSTAINABILITY INITIATIVES
    • 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN MULTIPLEX ASSAYS
      • 7.2.1.1 Eco-friendly initiatives
  • 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES

8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • 8.5 MARKET PROFITABILITY
    • 8.5.1 REVENUE POTENTIAL
    • 8.5.2 COST DYNAMICS
    • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE

  • 9.1 INTRODUCTION
  • 9.2 CONSUMABLES
    • 9.2.1 RECURRENT REQUIREMENTS AND PURCHASES OF CONSUMABLES TO DRIVE MARKET
  • 9.3 INSTRUMENTS
    • 9.3.1 LAUNCH OF TECHNOLOGICALLY ADVANCED INSTRUMENTS TO SUPPORT MARKET GROWTH
  • 9.4 SOFTWARE & SERVICES
    • 9.4.1 INCREASING NEED FOR EFFECTIVE DATA MANAGEMENT WITHIN LABORATORIES TO FUEL UPTAKE OF ADVANCED SOFTWARE

10 MULTIPLEX ASSAY MARKET, BY TYPE

  • 10.1 INTRODUCTION
  • 10.2 PROTEIN MULTIPLEX ASSAYS
    • 10.2.1 BEAD-BASED PROTEIN ASSAYS
      • 10.2.1.1 Best suited to study protein-protein interactions
    • 10.2.2 PLANAR PROTEIN ASSAYS
      • 10.2.2.1 Pivotal role in drug discovery to support uptake
    • 10.2.3 OTHER PROTEIN ASSAYS
  • 10.3 NUCLEIC ACID MULTIPLEX ASSAYS
    • 10.3.1 BEAD-BASED NUCLEIC ACID ASSAYS
      • 10.3.1.1 Increasing infectious diseases and genetic screening tests to drive market
    • 10.3.2 PLANAR NUCLEIC ACID ASSAYS
      • 10.3.2.1 Planar multiplex assays preferred in gene expression analysis, SNP genotyping, and transcriptome analysis
    • 10.3.3 OTHER NUCLEIC ACID ASSAYS
  • 10.4 CELL-BASED MULTIPLEX ASSAYS
    • 10.4.1 BETTER VARIABILITY THAN BIOCHEMICAL-BASED ASSAYS TO DRIVE MARKET

11 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY

  • 11.1 INTRODUCTION
  • 11.2 FLOW CYTOMETRY
    • 11.2.1 WIDE APPLICATIONS IN PROTEIN EXPRESSION, RNA, AND CELL HEALTH STATUS TO DRIVE SEGMENT
  • 11.3 FLUORESCENCE DETECTION
    • 11.3.1 INCREASING USE OF MICROARRAY SCANNERS AND FLUORESCENCE MICROSCOPES TO FUEL SEGMENT GROWTH
  • 11.4 MULTIPLEX REAL-TIME PCR
    • 11.4.1 HIGH SPECIFICITY AND SENSITIVITY OF MULTIPLEX REAL-TIME PCR TO DRIVE ADOPTION OF MULTIPLEX ASSAYS
  • 11.5 LUMINESCENCE
    • 11.5.1 RAPID AND EASY-TO-USE BENEFITS OF LUMINESCENCE TECHNOLOGY TO DRIVE MARKET
  • 11.6 NEXT-GENERATION SEQUENCING (NGS)
    • 11.6.1 RISING ADOPTION OF CUSTOMIZED AND APPLICATION-SPECIFIC NGS MULTIPLEX PANELS TO DRIVE MARKET
  • 11.7 OTHER TECHNOLOGIES

12 MULTIPLEX ASSAY MARKET, BY APPLICATION

  • 12.1 INTRODUCTION
  • 12.2 RESEARCH & DEVELOPMENT
    • 12.2.1 DRUG DISCOVERY & DEVELOPMENT
      • 12.2.1.1 Multiplex assays massively employed in preclinical and clinical phases
    • 12.2.2 BIOMARKER DISCOVERY & VALIDATION
      • 12.2.2.1 Advancing biomarker discovery through global collaborative research networks
  • 12.3 CLINICAL DIAGNOSTICS
    • 12.3.1 INFECTIOUS DISEASES
      • 12.3.1.1 Growing prevalence of infectious diseases to drive uptake of multiplex assays
    • 12.3.2 CANCER
      • 12.3.2.1 Rising burden of cancer to drive market
    • 12.3.3 CARDIOVASCULAR DISEASES
      • 12.3.3.1 High burden of cardiovascular diseases to support market growth
    • 12.3.4 AUTOIMMUNE DISEASES
      • 12.3.4.1 High incidence and prevalence of autoimmune diseases to drive demand for measures promoting early diagnosis
    • 12.3.5 NERVOUS SYSTEM DISORDERS
      • 12.3.5.1 Growing prevalence of nervous system disorders to fuel uptake of multiplex assays for early diagnosis and treatment
    • 12.3.6 METABOLISM & ENDOCRINOLOGY DISORDERS
      • 12.3.6.1 Multiplex assays used to measure endocrine and metabolic biomarkers help in timely diagnosis
    • 12.3.7 OTHER DISEASES

13 MULTIPLEX ASSAY MARKET, BY END USER

  • 13.1 INTRODUCTION
  • 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 13.2.1 GROWING DEMAND FOR MULTIPLEX ASSAYS IN DRUG DISCOVERY & CLINICAL STUDIES TO DRIVE MARKET
  • 13.3 HOSPITALS & DIAGNOSTIC LABORATORIES
    • 13.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE MARKET
  • 13.4 ACADEMIC & RESEARCH INSTITUTES
    • 13.4.1 RISING GOVERNMENT FUNDING TO ACCELERATE MULTIPLEX ADOPTION IN ACADEMIC RESEARCH
  • 13.5 CONTRACT RESEARCH ORGANIZATIONS
    • 13.5.1 RISING OUTSOURCING OF DRUG DEVELOPMENT ACTIVITIES TO ACCELERATE MULTIPLEX ASSAY ADOPTION AMONG CROS
  • 13.6 OTHER END USERS

14 MULTIPLEX ASSAY MARKET, BY REGION

  • 14.1 INTRODUCTION
  • 14.2 NORTH AMERICA
    • 14.2.1 US
      • 14.2.1.1 Increasing prevalence of infectious diseases and cancer to drive market
    • 14.2.2 CANADA
      • 14.2.2.1 Favorable government initiatives to fuel market
  • 14.3 EUROPE
    • 14.3.1 GERMANY
      • 14.3.1.1 Strong healthcare infrastructure to drive market
    • 14.3.2 UK
      • 14.3.2.1 Expansion of diagnostic infrastructure to drive market
    • 14.3.3 FRANCE
      • 14.3.3.1 Strong R&D investments and growing disease burden to drive market
    • 14.3.4 ITALY
      • 14.3.4.1 Growing adoption of advanced diagnostics to drive market
    • 14.3.5 SPAIN
      • 14.3.5.1 Rising disease burden to drive market
    • 14.3.6 REST OF EUROPE
  • 14.4 ASIA PACIFIC
    • 14.4.1 CHINA
      • 14.4.1.1 Strong healthcare investments to drive market
    • 14.4.2 JAPAN
      • 14.4.2.1 Universal healthcare reimbursement policy to foster market growth
    • 14.4.3 INDIA
      • 14.4.3.1 Increased private and public investments to bolster growth
    • 14.4.4 REST OF ASIA PACIFIC
  • 14.5 LATIN AMERICA
    • 14.5.1 BRAZIL
      • 14.5.1.1 Rising disease burden and expanding research ecosystem to drive market
    • 14.5.2 MEXICO
      • 14.5.2.1 Rising chronic disease burden to drive market
    • 14.5.3 REST OF LATIN AMERICA
  • 14.6 MIDDLE EAST & AFRICA
    • 14.6.1 GROWING HEALTHCARE INVESTMENTS AND RISING DEMAND FOR MULTIPLEX TESTING TO DRIVE MARKET

15 COMPETITIVE LANDSCAPE

  • 15.1 INTRODUCTION
  • 15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023-2026
    • 15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MULTIPLEX ASSAY MARKET
  • 15.3 REVENUE ANALYSIS, 2023-2025
  • 15.4 MARKET SHARE ANALYSIS, 2025
    • 15.4.1 MARKET SHARE ANALYSIS, 2025
  • 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 15.5.1 STARS
    • 15.5.2 EMERGING LEADERS
    • 15.5.3 PERVASIVE PLAYERS
    • 15.5.4 PARTICIPANTS
    • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 15.5.5.1 Company footprint
      • 15.5.5.2 Region footprint
      • 15.5.5.3 Product & service footprint
      • 15.5.5.4 Application footprint
      • 15.5.5.5 End user footprint
  • 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 15.6.1 PROGRESSIVE COMPANIES
    • 15.6.2 RESPONSIVE COMPANIES
    • 15.6.3 DYNAMIC COMPANIES
    • 15.6.4 STARTING BLOCKS
    • 15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
      • 15.6.5.1 Detailed list of key startups/SMEs
      • 15.6.5.2 Competitive benchmarking of key startups/SMEs (1/2)
      • 15.6.5.3 Competitive benchmarking of key startups/SMEs (2/2)
  • 15.7 COMPANY VALUATION AND FINANCIAL METRICS
    • 15.7.1 FINANCIAL METRICS
    • 15.7.2 COMPANY VALUATION
  • 15.8 BRAND/PRODUCT COMPARISON
  • 15.9 COMPETITIVE SCENARIO
    • 15.9.1 PRODUCT LAUNCHES & APPROVALS
    • 15.9.2 DEALS
    • 15.9.3 EXPANSIONS

16 COMPANY PROFILES

  • 16.1 KEY PLAYERS
    • 16.1.1 ILLUMINA, INC.
      • 16.1.1.1 Business overview
      • 16.1.1.2 Products offered
      • 16.1.1.3 Recent developments
        • 16.1.1.3.1 Product launches & approvals
        • 16.1.1.3.2 Deals
      • 16.1.1.4 MnM view
        • 16.1.1.4.1 Right to win
        • 16.1.1.4.2 Strategic choices
        • 16.1.1.4.3 Weaknesses & competitive threats
    • 16.1.2 BIO-RAD LABORATORIES, INC.
      • 16.1.2.1 Business overview
      • 16.1.2.2 Products offered
      • 16.1.2.3 Recent developments
        • 16.1.2.3.1 Product launches & approvals
        • 16.1.2.3.2 Deals
      • 16.1.2.4 MnM view
        • 16.1.2.4.1 Right to win
        • 16.1.2.4.2 Strategic choices
        • 16.1.2.4.3 Weaknesses & competitive threats
    • 16.1.3 THERMO FISHER SCIENTIFIC INC.
      • 16.1.3.1 Business overview
      • 16.1.3.2 Products offered
      • 16.1.3.3 Recent developments
        • 16.1.3.3.1 Product launches & approvals
        • 16.1.3.3.2 Deals
      • 16.1.3.4 MnM view
        • 16.1.3.4.1 Right to win
        • 16.1.3.4.2 Strategic choices
        • 16.1.3.4.3 Weaknesses & competitive threats
    • 16.1.4 DIASORIN S.P.A.
      • 16.1.4.1 Business overview
      • 16.1.4.2 Products offered
      • 16.1.4.3 Recent developments
        • 16.1.4.3.1 Product launches & approvals
        • 16.1.4.3.2 Deals
      • 16.1.4.4 MnM view
        • 16.1.4.4.1 Right to win
        • 16.1.4.4.2 Strategic choices
        • 16.1.4.4.3 Weaknesses & competitive threats
    • 16.1.5 BIOMERIEUX
      • 16.1.5.1 Business overview
      • 16.1.5.2 Products offered
      • 16.1.5.3 Recent developments
        • 16.1.5.3.1 Product launches & approvals
        • 16.1.5.3.2 Deals
      • 16.1.5.4 MnM view
        • 16.1.5.4.1 Right to win
        • 16.1.5.4.2 Strategic choices
        • 16.1.5.4.3 Weaknesses & competitive threats
    • 16.1.6 BECTON, DICKINSON AND COMPANY
      • 16.1.6.1 Business overview
      • 16.1.6.2 Products offered
      • 16.1.6.3 Recent developments
        • 16.1.6.3.1 Product launches & approvals
        • 16.1.6.3.2 Deals
    • 16.1.7 QIAGEN N.V.
      • 16.1.7.1 Business overview
      • 16.1.7.2 Products offered
      • 16.1.7.3 Recent developments
        • 16.1.7.3.1 Product launches & approvals
        • 16.1.7.3.2 Deals
    • 16.1.8 MERCK KGAA
      • 16.1.8.1 Business overview
      • 16.1.8.2 Products offered
      • 16.1.8.3 Recent developments
        • 16.1.8.3.1 Deals
        • 16.1.8.3.2 Expansions
    • 16.1.9 AGILENT TECHNOLOGIES, INC.
      • 16.1.9.1 Business overview
      • 16.1.9.2 Products offered
      • 16.1.9.3 Recent developments
        • 16.1.9.3.1 Product launches & approvals
        • 16.1.9.3.2 Deals
    • 16.1.10 DANAHER CORPORATION
      • 16.1.10.1 Business overview
      • 16.1.10.2 Products offered
      • 16.1.10.3 Recent developments
        • 16.1.10.3.1 Product launches & approvals
        • 16.1.10.3.2 Deals
    • 16.1.11 REVVITY, INC.
      • 16.1.11.1 Business overview
      • 16.1.11.2 Products offered
      • 16.1.11.3 Recent developments
        • 16.1.11.3.1 Product launches & approvals
        • 16.1.11.3.2 Deals
    • 16.1.12 F. HOFFMANN-LA ROCHE LTD
      • 16.1.12.1 Business overview
      • 16.1.12.2 Products offered
      • 16.1.12.3 Recent developments
        • 16.1.12.3.1 Product launches & approvals
        • 16.1.12.3.2 Deals
    • 16.1.13 QUANTERIX CORPORATION
      • 16.1.13.1 Business overview
      • 16.1.13.2 Products offered
      • 16.1.13.3 Recent developments
        • 16.1.13.3.1 Product launches & approvals
        • 16.1.13.3.2 Deals
  • 16.2 OTHER PLAYERS
    • 16.2.1 BIO-TECHNE CORPORATION
    • 16.2.2 SEEGENE INC.
    • 16.2.3 MESO SCALE DIAGNOSTICS LLC
    • 16.2.4 RANDOX LABORATORIES LTD.
    • 16.2.5 STANDARD BIOTOOLS INC.
    • 16.2.6 HOLOGIC, INC.
    • 16.2.7 ABBOTT LABORATORIES
    • 16.2.8 SIEMENS HEALTHINEERS AG
    • 16.2.9 ENZO BIOCHEM INC.
    • 16.2.10 SHIMADZU CORPORATION
    • 16.2.11 PROMEGA CORPORATION
    • 16.2.12 BOSTER BIOLOGICAL TECHNOLOGY

17 RESEARCH METHODOLOGY

  • 17.1 RESEARCH DATA
    • 17.1.1 SECONDARY RESEARCH
      • 17.1.1.1 Key data from secondary sources
    • 17.1.2 PRIMARY DATA
      • 17.1.2.1 Primary sources
      • 17.1.2.2 Key data from primary sources
      • 17.1.2.3 Key industry insights
  • 17.2 MARKET SIZE ESTIMATION
    • 17.2.1 BOTTOM-UP APPROACH
      • 17.2.1.1 Approach 1: Company revenue estimation approach
      • 17.2.1.2 Approach 2: Presentations of companies and primary interviews
      • 17.2.1.3 Growth forecast
    • 17.2.2 TOP-DOWN APPROACH
  • 17.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 17.4 MARKET SHARE ANALYSIS
  • 17.5 RESEARCH ASSUMPTIONS
    • 17.5.1 PARAMETRIC ASSUMPTIONS
    • 17.5.2 GROWTH RATE ASSUMPTIONS
  • 17.6 RESEARCH LIMITATIONS
  • 17.7 RISK ASSESSMENT

18 APPENDIX

  • 18.1 DISCUSSION GUIDE
  • 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 18.3 CUSTOMIZATION OPTIONS
  • 18.4 RELATED REPORTS
  • 18.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV (ALL AGES): 2010, 2023, AND 2024 (MILLION PEOPLE)
  • TABLE 2 ESTIMATED NUMBER OF NEW CANCER CASES IN BOTH SEXES: AGE 0-85+, 2022-2045
  • TABLE 3 TOTAL TB INCIDENCE, 2024
  • TABLE 4 IMPACT OF PORTER'S FIVE FORCES ON MULTIPLEX ASSAY MARKET
  • TABLE 5 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023-2030
  • TABLE 6 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 7 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 8 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 9 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 10 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 11 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY KEY PLAYER, 2024-2026 (USD)
  • TABLE 12 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY REGION, 2024-2026 (USD)
  • TABLE 13 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 14 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 15 MULTIPLEX ASSAY MARKET: KEY CONFERENCES AND EVENTS, 2026-2027
  • TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 17 KEY PATENTS IN MULTIPLEX ASSAY MARKET, 2022-2026
  • TABLE 18 KEY COMPANIES IMPLEMENTING AI IN MULTIPLEX ASSAY MARKET
  • TABLE 19 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 22 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 23 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
  • TABLE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • TABLE 26 ADOPTION BARRIERS AND INTERNAL CHALLENGES
  • TABLE 27 MULTIPLEX ASSAY MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • TABLE 28 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 29 MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 30 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 31 EUROPE: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 32 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 33 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 34 GLOBAL: NUMBER OF MULTIPLEX ANALYZERS INSTALLED, 2024-2031 (UNITS)
  • TABLE 35 MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 36 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 37 EUROPE: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 38 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 39 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 40 MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 41 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 42 EUROPE: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 44 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 45 MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 46 MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 47 MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 48 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 49 EUROPE: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 51 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 52 MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 53 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 54 EUROPE: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 56 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 57 MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 58 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 59 EUROPE: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 60 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 61 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 62 MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 63 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 64 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 65 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 66 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 67 SOME FDA-AUTHORIZED MULTIPLEX ASSAYS AND INSTRUMENTS FOR SIMULTANEOUS DETECTION OF INFLUENZA
  • TABLE 68 MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 69 MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 70 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 71 EUROPE: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 73 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 74 MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 75 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 76 EUROPE: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 77 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 78 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 79 MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 80 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 81 EUROPE: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 82 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 83 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 84 MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 85 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 86 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 87 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 88 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 89 MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 90 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 91 EUROPE: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 92 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 93 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 94 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 95 MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 96 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 97 EUROPE: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 99 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 100 MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 101 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 102 EUROPE: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 104 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 105 MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 106 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 107 EUROPE: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 108 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 109 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 110 MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 111 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 112 EUROPE: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 114 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 115 MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 116 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 117 EUROPE: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 119 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 120 MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 121 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 122 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 124 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 125 MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 126 MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 127 MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 128 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 129 EUROPE: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 130 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 131 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 132 MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 133 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 134 EUROPE: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 135 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 136 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 137 MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 138 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 139 EUROPE: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 140 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 141 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 142 MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 143 MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 144 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 145 EUROPE: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 146 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 147 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 148 MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 149 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 150 EUROPE: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 152 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 153 ESTIMATED NUMBER OF CANCER CASES IN BOTH SEXES (AGE 0-85+), BY REGION, 2022 VS. 2030
  • TABLE 154 MULTIPLEX ASSAY MARKET FOR CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 155 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 156 EUROPE: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 157 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 158 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 159 MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 160 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 161 EUROPE: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 162 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 163 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 164 MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 165 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 166 EUROPE: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 167 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 168 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 169 MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 170 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 171 EUROPE: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 172 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 173 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 174 MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 175 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 176 EUROPE: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 177 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 178 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 179 MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 180 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 181 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 183 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 184 MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 185 MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 186 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 187 EUROPE: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 188 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 189 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 190 MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 191 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 192 EUROPE: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 193 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 194 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 195 MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 196 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 197 EUROPE: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 198 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 199 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 200 MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 201 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 202 EUROPE: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 203 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 204 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 205 MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 206 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 207 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 208 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 209 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 210 MULTIPLEX ASSAY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 211 NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE
  • TABLE 212 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 213 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 214 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 215 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 216 NORTH AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 217 NORTH AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 218 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 219 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 220 NORTH AMERICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 221 NORTH AMERICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 222 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 223 US: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 224 US: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 225 US: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 226 US: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 227 US: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 228 US: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 229 US: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 230 US: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 231 US: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 232 CANADA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 233 CANADA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 234 CANADA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 235 CANADA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 236 CANADA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 237 CANADA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 238 CANADA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 239 CANADA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 240 CANADA: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 241 EUROPE: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE
  • TABLE 242 MACROECONOMIC INDICATORS FOR EUROPE
  • TABLE 243 EUROPE: MULTIPLEX ASSAY MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 244 EUROPE: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 245 EUROPE: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 246 EUROPE: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 247 EUROPE: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 248 EUROPE: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 249 EUROPE: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 250 EUROPE: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 251 EUROPE: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 252 EUROPE: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 253 GERMANY: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 254 GERMANY: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 255 GERMANY: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 256 GERMANY: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 257 GERMANY: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 258 GERMANY: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 259 GERMANY: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 260 GERMANY: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 261 GERMANY: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 262 UK: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 263 UK: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 264 UK: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 265 UK: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 266 UK: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 267 UK: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 268 UK: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 269 UK: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 270 UK: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 271 FRANCE: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 272 FRANCE: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 273 FRANCE: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 274 FRANCE: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 275 FRANCE: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 276 FRANCE: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 277 FRANCE: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 278 FRANCE: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 279 FRANCE: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 280 ITALY: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 281 ITALY: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 282 ITALY: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 283 ITALY: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 284 ITALY: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 285 ITALY: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 286 ITALY: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 287 ITALY: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 288 ITALY: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 289 SPAIN: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 290 SPAIN: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 291 SPAIN: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 292 SPAIN: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 293 SPAIN: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 294 SPAIN: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 295 SPAIN: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 296 SPAIN: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 297 SPAIN: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 298 REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 299 REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 300 REST OF EUROPE: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 301 REST OF EUROPE: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 302 REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 303 REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 304 REST OF EUROPE: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 305 REST OF EUROPE: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 306 REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 307 MACROECONOMIC INDICATORS FOR ASIA PACIFIC
  • TABLE 308 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 309 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 310 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 311 ASIA PACIFIC: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 312 ASIA PACIFIC: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 313 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 314 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 315 ASIA PACIFIC: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 316 ASIA PACIFIC: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 317 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 318 CHINA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 319 CHINA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 320 CHINA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 321 CHINA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 322 CHINA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 323 CHINA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 324 CHINA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 325 CHINA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 326 CHINA: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 327 JAPAN: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 328 JAPAN: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 329 JAPAN: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 330 JAPAN: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 331 JAPAN: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 332 JAPAN: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 333 JAPAN: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 334 JAPAN: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 335 JAPAN: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 336 INDIA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 337 INDIA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 338 INDIA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 339 INDIA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 340 INDIA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 341 INDIA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 342 INDIA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 343 INDIA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 344 INDIA: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 345 REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 346 REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 347 REST OF ASIA PACIFIC: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 348 REST OF ASIA PACIFIC: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 349 REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 350 REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 351 REST OF ASIA PACIFIC: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 352 REST OF ASIA PACIFIC: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 353 REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 354 MACROECONOMIC INDICATORS FOR LATIN AMERICA
  • TABLE 355 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 356 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 357 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 358 LATIN AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 359 LATIN AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 360 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 361 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 362 LATIN AMERICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 363 LATIN AMERICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 364 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 365 BRAZIL: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 366 BRAZIL: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 367 BRAZIL: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 368 BRAZIL: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 369 BRAZIL: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 370 BRAZIL: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 371 BRAZIL: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 372 BRAZIL: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 373 BRAZIL: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 374 MEXICO: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 375 MEXICO: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 376 MEXICO: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 377 MEXICO: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 378 MEXICO: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 379 MEXICO: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 380 MEXICO: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 381 MEXICO: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 382 MEXICO: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 383 REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 384 REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 385 REST OF LATIN AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 386 REST OF LATIN AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 387 REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 388 REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 389 REST OF LATIN AMERICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 390 REST OF LATIN AMERICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 391 REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 392 MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 393 MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 394 MIDDLE EAST & AFRICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 395 MIDDLE EAST & AFRICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 396 MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 397 MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 398 MIDDLE EAST & AFRICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 399 MIDDLE EAST & AFRICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 400 MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 401 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN MULTIPLEX ASSAY MARKET, JANUARY 2023-APRIL 2026
  • TABLE 402 MULTIPLEX ASSAY MARKET: DEGREE OF COMPETITION
  • TABLE 403 MULTIPLEX ASSAY MARKET: REGION FOOTPRINT
  • TABLE 404 MULTIPLEX ASSAY MARKET: PRODUCT & SERVICE FOOTPRINT
  • TABLE 405 MULTIPLEX ASSAY MARKET: APPLICATION FOOTPRINT
  • TABLE 406 MULTIPLEX ASSAY MARKET: END USER FOOTPRINT
  • TABLE 407 MULTIPLEX ASSAY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 408 MULTIPLEX ASSAY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES (1/2)
  • TABLE 409 MULTIPLEX ASSAY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES (2/2)
  • TABLE 410 MULTIPLEX ASSAY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 411 MULTIPLEX ASSAY MARKET: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 412 MERCK KGAA: EXPANSIONS, JANUARY 2023- APRIL 2026
  • TABLE 413 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 414 ILLUMINA, INC: PRODUCTS OFFERED
  • TABLE 415 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 416 ILLUMINA, INC.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 417 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 418 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
  • TABLE 419 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 420 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 421 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 422 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 423 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 424 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 425 DIASORIN S.P.A.: COMPANY OVERVIEW
  • TABLE 426 DIASORIN S.P.A.: PRODUCTS OFFERED
  • TABLE 427 DIASORIN S.P.A.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 428 DIASORIN S.P.A.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 429 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 430 BIOMERIEUX: PRODUCTS OFFERED
  • TABLE 431 BIOMERIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 432 BIOMERIEUX: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 433 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 434 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
  • TABLE 435 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 436 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 437 QIAGEN N.V.: COMPANY OVERVIEW
  • TABLE 438 QIAGEN N.V.: PRODUCTS OFFERED
  • TABLE 439 QIAGEN N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 440 QIAGEN N.V.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 441 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 442 MERCK KGAA: PRODUCTS OFFERED
  • TABLE 443 MERCK KGAA: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 444 MERCK KGAA: DEALS, JANUARY 2023- APRIL 2026
  • TABLE 445 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 446 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
  • TABLE 447 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 448 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 449 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 450 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 451 DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 452 DANAHER CORPORATION: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 453 REVVITY, INC.: COMPANY OVERVIEW
  • TABLE 454 REVVITY, INC.: PRODUCTS OFFERED
  • TABLE 455 REVVITY, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 456 REVVITY, INC.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 457 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 458 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
  • TABLE 459 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 460 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 461 QUANTERIX CORPORATION: COMPANY OVERVIEW
  • TABLE 462 QUANTERIX CORPORATION: PRODUCTS OFFERED
  • TABLE 463 QUANTERIX CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 464 QUANTERIX CORPORATION: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 465 BIO-TECHNE CORPORATION: COMPANY OVERVIEW
  • TABLE 466 SEEGENE INC.: COMPANY OVERVIEW
  • TABLE 467 MESO SCALE DIAGNOSTICS LLC: COMPANY OVERVIEW
  • TABLE 468 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW
  • TABLE 469 STANDARD BIOTOOLS INC.: COMPANY OVERVIEW
  • TABLE 470 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 471 ABBOTT LABORATORIES: COMPANY OVERVIEW
  • TABLE 472 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 473 ENZO BIOCHEM INC.: COMPANY OVERVIEW
  • TABLE 474 SHIMADZU CORPORATION: COMPANY OVERVIEW
  • TABLE 475 PROMEGA CORPORATION: COMPANY OVERVIEW
  • TABLE 476 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
  • TABLE 477 MULTIPLEX ASSAY MARKET: RISK ASSESSMENT

List of Figures

  • FIGURE 1 MULTIPLEX ASSAY MARKET SEGMENTATION
  • FIGURE 2 MARKET HIGHLIGHTS AND KEY INSIGHTS
  • FIGURE 3 MULTIPLEX ASSAY MARKET, 2024-2031
  • FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN MULTIPLEX ASSAY MARKET, 2023-2025
  • FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF MULTIPLEX ASSAY MARKET
  • FIGURE 6 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN MULTIPLEX ASSAY MARKET, 2026-2031
  • FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 8 RISING CASES OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
  • FIGURE 9 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 10 PROTEIN MULTIPLEX ASSAYS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 11 MULTIPLEX REAL-TIME PCR SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 12 RESEARCH & DEVELOPMENT SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 15 MULTIPLEX ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 16 MULTIPLEX ASSAY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 17 MULTIPLEX ASSAY MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 18 MULTIPLEX ASSAY MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 19 MULTIPLEX ASSAY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 20 MULTIPLEX ASSAY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 21 NUMBER OF DEALS AND FUNDING ACTIVITIES IN MULTIPLEX ASSAY MARKET
  • FIGURE 22 APPLIED AND GRANTED PATENTS, 2016-2025
  • FIGURE 23 MARKET POTENTIAL OF AI IN MULTIPLEX ASSAY MARKET
  • FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
  • FIGURE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • FIGURE 26 NORTH AMERICA: MULTIPLEX ASSAY MARKET SNAPSHOT
  • FIGURE 27 ASIA PACIFIC: MULTIPLEX ASSAY MARKET SNAPSHOT
  • FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN MULTIPLEX ASSAY MARKET, 2023-2025 (USD MILLION)
  • FIGURE 29 MULTIPLEX ASSAY MARKET SHARE ANALYSIS, 2025
  • FIGURE 30 MULTIPLEX ASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 31 MULTIPLEX ASSAY MARKET: COMPANY FOOTPRINT
  • FIGURE 32 MULTIPLEX ASSAY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 33 EV/EBITDA OF KEY VENDORS
  • FIGURE 34 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 35 MULTIPLEX ASSAY MARKET: BRAND/PRODUCT COMPARISON FOR MULTIPLEX INSTRUMENTS
  • FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 37 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 39 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025)
  • FIGURE 40 BIOMERIEUX: COMPANY SNAPSHOT (2025)
  • FIGURE 41 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2025)
  • FIGURE 42 QIAGEN N.V.: COMPANY SNAPSHOT (2025)
  • FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2025)
  • FIGURE 44 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 46 REVVITY, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 47 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
  • FIGURE 48 QUANTERIX CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 49 RESEARCH DESIGN
  • FIGURE 50 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 52 MULTIPLEX ASSAY MARKET: REVENUE SHARE ANALYSIS
  • FIGURE 53 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 54 TOP-DOWN APPROACH
  • FIGURE 55 DATA TRIANGULATION METHODOLOGY